



MicroRNA Prediction in the FVIII Gene Locus: A Step Towards Hemophilia A Control

Halimeh Rezaei¹, Majid Motovali-Bashi^{1,*} and Sheyda Khalilian¹

¹Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran

*Corresponding author: Associate Professor, Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran. Email: mbashi881@gmail.com

Received 2020 March 29; Revised 2020 April 25; Accepted 2020 April 30.

Abstract

Background: Various mutations in *factor VIII (F8)* gene locus are led to an X-linked bleeding disorder in patients with hemophilia A. One of the leading causes of inefficient treatment available for hemophilia A is the lack of specific and sensitive diagnostic procedure for the disease. The discovery of a functional role of microRNAs (miRNAs) in the pathogenesis of a wide range of human diseases makes them the potential, non-invasive, biomarker candidates for hemophilia A. Therefore, advances in computational tools for miRNA discovery leads to numerous recent publications on miRNAs as putative biomarkers.

Objectives: The current study aimed at scanning the *F8* gene region to predict novel miRNAs as regulators of the *F8* gene.

Methods: The potential of the FVIII locus to express new miRNAs was studied via reliable bioinformatics databases, such as SSCprofler, RNAfold, miREval, miR-Find, FOMmiR, UCSC genome browser, and miRBase.

Results: Data analysis from previously mentioned databases offered two stem-loop structures predicted to express novel miRNAs.

Conclusions: The presented stem-loop structures can be used as powerful non-invasive biomarkers in early diagnosis of the disease and regulation of the *factor VIII* gene after subsequent experimental verification.

Keywords: microRNAs, MiRNAs, Bioinformatics, Hemophilia A, Diagnosis, Biomarker

1. Background

Amongst the existing X-linked bleeding disorders, hemophilia A, with its recessive nature, is known as one of the most common ones. With the scientifically agreed-upon frequency of one in 5000 male births, the cause of this disorder is proved to be a sort of defect of the plasma protein involved in hemostasis called FVIII (1). Based on the natural function of FVIII, hemophilia A is subcategorized into three various levels of mild (> 5% - < 40%), moderate (1% - 5%) and severe (< 1%) (2), with the prevalence of 40%, 10%, and 50%, respectively (3). As an essentially functional plasma protein for the coagulation system of the human blood, FVIII is transformed into an inactive form via establishing a connection with the von Willebrand factor during the clotting process. When the body receives an injury, coagulation *factor VIII* activates and separates from the von Willebrand factor. The next step of the procedure of responding to injury is the interaction of *factor VIII* with another coagulation factor, *factor IX*. When these two factors interact with one another, a sequence of resultant chemical reactions leads to the coagulation of the blood (4).

With its exact location in the proximal segment of

chromosome Xq28, the human *FVIII (F8)* gene has the function of encoding the coagulation *factor VIII*. Approximately, the length of this gene is 186 kb, including 26 exons, which leads to the production of two transcripts, each of which is spliced alternatively. A respectively large glycoprotein, known as isoform a, is encoded by the transcript variant 1; correspondingly, a putative small protein, isoform b, is encoded by the transcript variant 2 (5). More than thousand different mutations are reported in the *F8* gene, including over 120 main deletions (< 50 bp); inversion in intron 1, which is accountable for 1% - 4% of patients with severe forms of hemophilia A; inversion in intron 22, which is accountable for nearly half of patients with severe forms of hemophilia A; and small substitutes and deletions of unspecified nature (6). More than 1000 mutations are archived thus far in the Hemophilia World Databank, also known as HAMSTeRs (7).

The microRNAs (miRNAs) are short non-coding RNAs with 18 - 25 nucleotides in length. Their predominant function is to work as the regulator of post-transcriptional gene expression.

Firstly, miRNAs are transcribed into the form of elon-

gated primary transcripts, namely pri-miRNA. Next, being processed by the Drosha enzyme and then the precursor miRNA (pre-miRNA), it is moved to the cytoplasm. In the cytoplasm, it undergoes further processing by the Dicer enzyme. Eventually, the mature miRNA is integrated into an RNA-induced silencing complex (RISC), attached to the 3' untranslated region (UTR) of the target messenger RNAs (mRNAs), specifically to mediate translational repression (8).

Allegedly, about 60% of all human genes are believed to be the reputed targets of single miRNAs since an individual miRNA is potent enough for targeting up to hundreds of genes. A complex regulatory network is additionally created since human genes might contain multiple binding sites for various miRNAs (9).

It is comprehensively elucidated that miRNAs are involved in various biological processes since they play a pivotal role in the pathogenesis process of different diseases and cancers.

The miRNA expression profiling signifies their tissue-specific patterns of expression; thus, they are considered as attractive biomarkers in diagnosis and treatment (10). Consequently, predicting and identifying parts of the genome that are susceptible to the expression of novel miRNAs, as well as registered miRNAs, leading to an outstanding opportunity for molecular studies of miRNAs, a target that can be acquired by both bioinformatics and molecular laboratory techniques (11).

2. Objectives

Hemophilia A is a monogenic disorder, and the majority of known and registered miRNAs in human genes influence the expression levels of its associated target gene; hence, the present study aimed at searching for the miRNAs embedded within the sequence of the *F8* gene to control the progression of hemophilia A.

3. Methods

Based upon the sequences of known registered miRNAs, the types of algorithms that can be utilized in databases and bioinformatics tools to identify and predict novel miRNAs are initially pinpointed. Such programs are subsequently used to scan the genome and detect the sequences of putative novel miRNAs. In other words, gathering, analyzing, and combining a vast amount of data on known and registered miRNAs reveals similar characteristics, including the bulge size and position, the content of the nucleotide, the thermodynamic stability, sequence complexity, the length of the stem-loop structure

and repetitive elements existing in the genes, which not only encode miRNAs but also are utilized in their prediction.

The current study employed the SSCprofler database, and investigated two novel stem-loop structures in the *F8* gene (<http://mirna.imbb.forth.gr/SSCprofler.html>) (12).

Biological information concerning factors, such as structure, sequence, and protection of human miRNAs, is provided by the SSCprofler database. On this database, the sensitivity and specificity of the output data are 84.16% and 95.88%, respectively (13). Moreover, the RNAfold web server (<http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi>) (14) was utilized to study the stem-loop structures and stability produced by the SSCprofler database. Processes, such as predicting secondary structures of single-stranded RNAs and calculating the base-pairing probability matrix, the partition function, and the structure of minimum free energy (MFE), are carried out by the RNAfold web server (15).

The following three web servers were used to assess the accuracy of the predicted stem-loop structures: miREval (<http://mimirna.centenary.org.au/mireval>) (16), FOMmiR (<http://app.shenwei.me/cgi-bin/FOMmiR.cgi>) (17), and MaturBayes (<http://mirna.imbb.forth.gr/MatureBayes.html>) (18). A support vector machine (SVM) trained on 57 distinct characteristics, such as sequence composition, secondary structure, and free energy, is utilized by the miREval web server. For the miREval database to differentiate miRNA stem-loops from stem-loops in other non-coding RNAs, two negative and positive categories of information are allocated to the SVM (16).

The FOMmiR database is capable of distinguishing the stem-loops from the precursors of miRNA, and also locates the position and strand of the mature miRNA. Therefore, this database represents a particular awareness upon biological recognition, which might be intently connected to the enzyme cleavage mechanism during the miRNA maturation (17). Besides, the MaturBayes database is a tool to detect mature miRNAs within the stem-loop structures, using a naive Bayes classifier.

Subsequently, the roles of the Dicer and Drosha enzymes were studied according to the stem-loop structure sequences, using the miR-FIND database (<http://140.120.14.132:8080/MicroRNAProject-Web>) (19).

Using the UCSC genome browser database (<https://genome.ucsc.edu>) (20), the conservation of the potential stem-loop structures in the vertebral genome was additionally analyzed. In 14 various human cell lines, the RNA expression profiling was investigated using deep sequencing technology; and the possibility of the novel miRNA expression in the potential sequence was assessed. Eventually, the miRBase database

(<http://www.mirbase.org/>) (21) was utilized to authenticate the novelty of the potent sequences as mature miRNAs. Significantly, the miRNA gene potential candidates did not demonstrate an obvious sequence similarity to the known miRNA genes (22). On this database, over 12,000 mature miRNAs from 600 distinct species are identified and registered.

4. Results

To identify and predict the stem-loop structures, the *F8* gene associated with hemophilia A was accordingly scanned. For this purpose, high reliable bioinformatics servers and related databases were utilized. Two stem-loop structures, namely, put-miR1 and put-miR2, with the sequences of "TGCTGCTGCCACTCAGGAAGAGGGTTGGAGTAGGCTAGGAATAGGAGCACAAATTAAGCTCCTGTTCACTTTGACTTCTCCATCCCTCTCCTCTTCCTTAA", and "TGATAAAGGCTCATAAAAGTTGAGGAAGCCATTTGGGCTCtctactccagcatgtccacagaccaggagtagcagcatcacctgagggcaattcaaatgca", respectively, both located in the first intron of the *F8* gene, were predicted and presented for experimental verification, with regard to the results.

4.1. SSCprofiler Database

Stem-loop structures in the *F8* gene are predicted and identified in this database. Moreover, the SSCprofiler database utilizes a hidden Markov model (HMM) to model secondary structural features in each position of miRNA stem-loops. The structure, sequencing, and conservation of the miRNA coding genes are simultaneously determined by this score in the statistical models; therefore, the higher the score, the greater the chance that the potential candidate structure belongs to the real miRNA (Figure 1A).

4.2. RNAfold Web Server

To make more precise studies on the stability of the secondary structures, the stem-loop structures proposed by the SSCprofiler database were introduced in this server. Concerning the amount of minimum free energy apportioned amongst structures, the stability of the proposed secondary structures was investigated (Figure 1B). The MFE for put-miR1 and put-miR2 was -41.8 and -35.1 kcal.mol⁻¹, respectively.

4.3. The miREval Web Tool

Through this web tool, the accuracy of the stem-loop structures was assessed (Figure 1C).

4.4. FOMmiR and MatureBayes Web Tools

Via FOMmiR and MatureBayes web tools, the predicted results for mature miRNAs in the candidate sequences, as well as the accuracy of the formation of secondary structures, were investigated (Figure 2A and B).

4.5. The miRFIND Database

Drosha and Dicer cleavage sites were identified in the candidate sequences and shown in Table 1.

4.6. The UCSC Genome Browser

The percentage of sequences conservation among 100 vertebral genomes (Figure 2C), as well as the deep sequencing data (Figure 3), was analyzed. Conclusively, the results revealed that put-miR1 and put-miR2 were expressed in IMR90 CIP-TAP, IMR90, SKMC cells, and A549 CIP-TAP, HPC-PL TAP-only, IMR90 cells, respectively.

4.7. The MiRBase Database

This database was utilized to ensure that the candidate sequences were not reported as a mature miRNA in other previously published studies.

5. Discussion

Nowadays, treatment decisions, as well as detection of recurrent disease and monitoring therapy, are mostly performed by predictive and diagnostic biomarkers (23).

Appropriate biomarkers should be stable and non-invasive, and ought to be disease-specific for reliable and accurate measurement across a diseased population (24). It is recommended that due to the prevalence of miRNA regulation, it should participate in a wide range of human-specific diseases. It is proposed that such regulators have critical functions, such as oncogenes or tumor suppressor genes in various types of cancers (25). For instance, miR-16, as well as miR-15, frequently undergo deletion in different types of leukemia (26) and miR-182, miR-96, and miR-183 expressions correlate with the progression of non-small cell lung cancer (27). Also, miR-423-5P (28), miR-16 (29), miR-139-5P (30), miR-182, and miR-187 (31) are among the detected miRNAs used as biomarkers in cancer diagnosis. They are also involved in some other diseases, such as immunological, psychiatric, and neurodegenerative ones (32). Down-regulation of the biogenesis factors (33), a mutation in the miRNA locus (34), or epigenetic changes-e.g., hypermethylation (35), can perturb the miRNA function. Prior to investigating the role of miRNA in a disease, it should be predicted and annotated, according to its specific expression pattern. Then, by artificially altering the expression level of miRNAs, the initiation and progression of the diseases




Figure 1. Using SSCprofiler, RNAfold, and miREval to predict put-miR1 and put-miR2 within the first intron of the human *F8* gene, respectively. A-1, A-2: Results of SSCprofiler for put-miR1 and put-miR2. Hairpin structures containing a probable sequence of mature miR (red) are shown, and HMM scores related to these structures are shown in the table. Furthermore, maximum expression (max-expression), according to a full genome tiling array in the HeLa cell line is presented for these sequences. B-1, B-2: Graphical output of hairpin structures in RNAfold web server. Secondary structure results of put-miR1 and put-miR2 are depicted. C-1, C-2: miREval output data; 1000 base pairs around our inquiry sequences are displayed as a circle graph by miREval.

Table 1. Information Analyzed in the miR-Find^a

| Sequence | Put-miR1 | | Put-miR2 | |
|-------------------------------------|------------------------------------|------------------------------------|-------------------------------------|-----------------------------------|
| Mature-miRNA | 23/46 | 82/59 | 20/42 | 79/58 |
| Drosha/Dicer processing site | | | | |
| Mature-miRNA sequence | 5- UUGGAGUAGGCUAGGAAUAGGA- 3 | 5- UCCGUUUCACUUUGACUUCUCC/ 3 | 5- AUGGAGAAGUCAAAAGUGAACAGG 3 | 5- UCCUAUUCUAGCCUACUCCAA- 3 |
| Predicted seed site | 5-UGGAGUA-3 | 5-CCUGUUC-3 | 5-UGGAGAA-3 | 5-CCUAUUC-3 |

^aData corresponding to the mature -5p (red) and miRNA-3p (black) are presented.

could be controlled. This issue is used to treat cardiovascular diseases-eg, cardiopulmonary resuscitation (36), cardiac calcium signaling (37), and cardiac repair after myocardial infarction (38). Thus, predicting miRNA is a substantial step of primary analysis in the clinical context.

The discovery of novel miRNAs eventually results in an alteration in treatment attitudes, enhanced clinical results, higher allocation of health care resources, and increased utilization of miRNA-based therapy (39). More miRNAs are detected by extensive cloning and sequencing. The major limitation of miRNA detection by cloning is that it is troublesome to find miRNAs with low expression levels, expressed per cell at different stages of development, or exhibit tissue-restricted expression. Nevertheless,

the process of miRNA cloning, according to their physical characteristics, such as post-translational modifications or nucleotide sequences, is not easily achieved. Additionally, expensive and time-consuming cloning techniques added more limitations as well (40). Computational algorithms can be used to provide quick, efficient, and inexpensive methods to detect and predict miRNA coding sequences in the genome. It should be confirmed in-vitro by examining the expression of the endogenous miRNA mature form (41).

Lai et al., according to the expression profiling and bioinformatics analyses, suggested about 24 new target genes for human miRNAs (42); furthermore, Hoballa et al., consistent to the bioinformatics prediction, introduced

19. Jiang P, Wu H, Wang W, Ma W, Sun X, Lu Z. MiPred: classification of real and pseudo microRNA precursors using random forest prediction model with combined features. *Nucleic Acids Res.* 2007;**35**(Web Server issue):W339–44. doi: [10.1093/nar/gkm368](https://doi.org/10.1093/nar/gkm368). [PubMed: [17553836](https://pubmed.ncbi.nlm.nih.gov/17553836/)]. [PubMed Central: [PMC1933124](https://pubmed.ncbi.nlm.nih.gov/PMC1933124/)].
20. Haeussler M, Zweig AS, Tyner C, Speir ML, Rosenbloom KR, Raney BJ, et al. The UCSC genome browser database: 2019 update. *Nucleic acids research.* 2018;**47**(D1):D853–8.
21. Kozomara A, Birgaonu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. *Nucleic acids research.* 2018;**47**(D1):D155–62.
22. Cowled C, Stewart CR, Likic VA, Friedlander MR, Tachedjian M, Jenkins KA, et al. Characterisation of novel microRNAs in the Black flying fox (*Pteropus alecto*) by deep sequencing. *BMC Genomics.* 2014;**15**:682. doi: [10.1186/1471-2164-15-682](https://doi.org/10.1186/1471-2164-15-682). [PubMed: [25128405](https://pubmed.ncbi.nlm.nih.gov/25128405/)]. [PubMed Central: [PMC4156645](https://pubmed.ncbi.nlm.nih.gov/PMC4156645/)].
23. Selleck MJ, Senthil M, Wall NR. Making Meaningful Clinical Use of Biomarkers. *Biomark Insights.* 2017;**12**:1.1772719177152E+15. doi: [10.1177/1177271917715236](https://doi.org/10.1177/1177271917715236). [PubMed: [28659713](https://pubmed.ncbi.nlm.nih.gov/28659713/)]. [PubMed Central: [PMC5479428](https://pubmed.ncbi.nlm.nih.gov/PMC5479428/)].
24. Byrnes SA, Weigl BH. Selecting analytical biomarkers for diagnostic applications: a first principles approach. *Expert Rev Mol Diagn.* 2018;**18**(1):19–26. doi: [10.1080/14737159.2018.1412258](https://doi.org/10.1080/14737159.2018.1412258). [PubMed: [29200322](https://pubmed.ncbi.nlm.nih.gov/29200322/)].
25. Vannini I, Fanini F, Fabbri M. Emerging roles of microRNAs in cancer. *Current opinion in genetics & development.* 2018;**48**:128–33.
26. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proceedings of the National Academy of Sciences.* 2005;**102**(39):13944–9.
27. Tan W, Liu B, Qu S, Liang G, Luo W, Gong C. MicroRNAs and cancer: Key paradigms in molecular therapy. *Oncology letters.* 2018;**15**(3):2735–42.
28. Tijssen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. MiR423-5p as a circulating biomarker for heart failure. *Circulation research.* 2010;**106**(6):1035.
29. Wang H, Zhang P, Chen W, Feng D, Jia Y, Xie L. Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects. *Clinical chemistry and laboratory medicine.* 2012;**50**(8):1423–8.
30. Miyoshi J, Toden S, Yoshida K, Toiyama Y, Alberts SR, Kusunoki M, et al. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. *Scientific reports.* 2017;**7**:43393.
31. Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masià E, Casanova J, et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. *The Journal of urology.* 2014;**192**(1):252–9.
32. Esteller M. Non-coding RNAs in human disease. *Nature Reviews Genetics.* 2011;**12**(12):861.
33. Kang W, Friedländer MR. Computational prediction of miRNA genes from small RNA sequencing data. *Frontiers in bioengineering and biotechnology.* 2015;**3**:7.
34. Mencía Á, Modamio-Høybjør S, Redshaw N, Morín M, Mayo-Merino F, Olavarrieta L, et al. Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. *Nature genetics.* 2009;**41**(5):609.
35. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. *Oncogene.* 2012;**31**(16):2062.
36. Wu G, Huang Z, Wang D. MicroRNAs in cardiac regeneration and cardiovascular disease. *Science China Life Sciences.* 2013;**56**(10):907–13.
37. Harada M, Luo X, Murohara T, Yang B, Dobrev D, Nattel S. MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. *Circulation research.* 2014;**114**(4):689–705.
38. Sahoo S, Losordo DW. Exosomes and cardiac repair after myocardial infarction. *Circulation research.* 2014;**114**(2):333–44.
39. Monroig PDC, Calin GA. MicroRNA and epigenetics: diagnostic and therapeutic opportunities. *Current pathobiology reports.* 2013;**1**(1):43–52.
40. Vanas V, Haigl B, Stockhammer V, Sutterlüty-Fall H. MicroRNA-21 increases proliferation and cisplatin sensitivity of osteosarcoma-derived cells. *PLoS one.* 2016;**11**(8). e0161023.
41. Zhang Y, Huang H, Zhang D, Qiu J, Yang J, Wang K, et al. A review on recent computational methods for predicting noncoding RNAs. *BioMed research international.* 2017;**2017**.
42. Lai EC, Tomancak P, Williams RW, Rubin GM. Computational identification of Drosophila microRNA genes. *Genome biology.* 2003;**4**(7):R42.
43. Hoballa MH, Soltani BM, Mowla SJ, Sheikhpour M, Kay M. Identification of a novel intergenic miRNA located between the human DDC and COBL genes with a potential function in cell cycle arrest. *Mol Cell Biochem.* 2018;**444**(1-2):179–86. doi: [10.1007/s11010-017-3242-3](https://doi.org/10.1007/s11010-017-3242-3). [PubMed: [29198020](https://pubmed.ncbi.nlm.nih.gov/29198020/)].
44. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. *Nat Genet.* 2005;**37**(7):766–70. doi: [10.1038/ng1590](https://doi.org/10.1038/ng1590). [PubMed: [15965474](https://pubmed.ncbi.nlm.nih.gov/15965474/)].
45. Dokanehiifard S, Yasari A, Najafi H, Jafarzadeh M, Nikkha M, Mowla SJ, et al. A novel microRNA located in the TrkC gene regulates the Wnt signaling pathway and is differentially expressed in colorectal cancer specimens. *J Biol Chem.* 2017;**292**(18):7566–77. doi: [10.1074/jbc.M116.760710](https://doi.org/10.1074/jbc.M116.760710). [PubMed: [28100780](https://pubmed.ncbi.nlm.nih.gov/28100780/)]. [PubMed Central: [PMC5418054](https://pubmed.ncbi.nlm.nih.gov/PMC5418054/)].
46. Dokanehiifard S, Soltani BM, Parsi S, Hosseini F, Javan M, Mowla SJ. Experimental verification of a conserved intronic microRNA located in the human TrkC gene with a cell type-dependent apoptotic function. *Cellular and molecular life sciences.* 2015;**72**(13):2613–25.
47. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP. Vertebrate microRNA genes. *Science.* 2003;**299**(5612):1540.
48. Wu Q, Wang C, Guo L, Ge Q, Lu Z. Identification and characterization of novel microRNA candidates from deep sequencing. *Clinica chimica acta.* 2013;**415**:239–44.